pages/clinical.md
... ...
@@ -11,8 +11,8 @@ link-citations: true
11 11
|[BCL2](/BCL2)|not approved|therapeutic target|DLBCL|venetoclax|Not applicable|
12 12
|[BTK](/BTK#clinical-relevance)|not approved|therapeutic target|DLBCL|ibrutinib|ABC gene expression signature, MCD genetic subgroup|
13 13
|[CD79B](/CD79B#clinical-relevance)|FDA approved|therapeutic target|DLBCL|polatuzumab vedotin|ABC gene expression signature|
14
-|[EZH2](/EZH2#clinical-relevance)|therapeutic target|FL|tazemetostat|Mutation|
15
-|[XPO1](/XPO1#clinical-relevance)|therapeutic target|DLBCL|selinexor|Not applicable|
14
+|[EZH2](/EZH2#clinical-relevance)|FDA approved|therapeutic target|FL|tazemetostat|Mutation|
15
+|[XPO1](/XPO1#clinical-relevance)|FDA approved|therapeutic target|DLBCL|selinexor|Not applicable|
16 16
17 17
18 18
## References